Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene and protein expression profiles after treatment of actinic keratosis
2021-005996-37Phase 2Completed
- Sponsor
- Zealand University Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of melatonin, fluorouracil and imiquimod in actinic keratosis (AK) (3 arms), sponsored by Zealand University Hospital. Primary endpoint: Differences in gene and protein expression in actinic keratoses. Started Jan 2022; status: completed.
02
Drugs
melatoninfluorouracilimiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2021-005996-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005996-37.